SCHEMBL164980

SCHEMBL164980

CC(C)[C@@](C)(N)C(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL62851 1.00
SCHEMBL62852 1.00
SCHEMBL723877 1.00 CYP2D6 (0.41)
Hydrochloric Acid SCHEMBL18281053 0.97 CYP2D6 (0.40)
Hydrochloric Acid SCHEMBL17140724 0.97 CYP2D6 (0.40)
SCHEMBL8741964 0.97 CYP2D6 (0.40)
Hydrochloric Acid SCHEMBL247261 0.97 CYP2D6 (0.40)
SCHEMBL8741958 0.97 CYP2D6 (0.40)
SCHEMBL16150185 0.88 CYP1A2 (0.35)
SCHEMBL3979627 0.80

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1838 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4267590-A1 ARGINASE INHIBITORS AND METHODS OF USE THEREOF ONCOARENDI THERAPEUTICS S.A. (PL) 2023-11-01 EP claimed
US-20220204530-A1 ARGINASE INHIBITORS AND METHODS OF USE THEREOF MOLECURE S.A. (PL) 2022-06-30 US claimed
WO-2022137156-A1 ARGINASE INHIBITORS AND METHODS OF USE THEREOF Oncoarendi Therapeutics S.A. (PL) 2022-06-30 WO claimed
EP-3008062-B1 PRODRUG DERIVATIVES OF SUBSTITUTED TRIAZOLOPYRIDINES Bayer Pharma AG (DE) 2017-04-05 EP claimed
CN-105377848-A Prodrug derivatives of substituted triazolopyridines Bayer Pharma AG 2016-03-02 CN claimed
WO-2013004716-A1 PEPTIDE BEADS UNIVERSITÄT BASEL (CH) 2013-01-10 WO claimed
US-20090215895-A1 Therapeutic and carrier molecules PEPLIN BIOLIPIDS PTY LTD (AU) 2009-08-27 US claimed
EP-1718602-A4 THERAPEUTIC AND CARRIER MOLECULES PEPLIN BIOLIPIDS PTY LTD (AU) 2007-12-12 EP claimed
US-7256172-B1 Method of treatment and agents useful for same THE UNIVERSITY OF MELBOURNE (AU) 2007-08-14 US claimed
EP-1718602-A1 THERAPEUTIC AND CARRIER MOLECULES Peplin Biolipids Pty Ltd. (AU) 2006-11-08 EP claimed
WO-2005073164-A1 THERAPEUTIC AND CARRIER MOLECULES PEPLIN BIOLIPIDS PTY LTD (AU) 2005-08-11 WO claimed
WO-2026085582-A1 PROTEIN CAGES THE UNIVERSITY OF SYDNEY (AU) 2026-04-30 WO disclosed
US-12612420-B2 Arginase inhibitors and methods of use thereof MOLECURE S.A. (PL) 2026-04-28 US disclosed
US-20250361273-A1 METHODS AND COMPOSITIONS FLAGSHIP PIONEERING INNOVATIONS VII, LLC 2025-11-27 US disclosed
EP-4627079-A2 THERMOSTABLE BINDING SCAFFOLDS Nectagen, Inc. (US) 2025-10-08 EP disclosed
EP-0745092-A1 PEPTIDE INHIBITORS OF UROKINASE RECEPTOR ACTIVITY CHIRON CORPORATION (US) 1996-12-04 EP disclosed
EP-0672049-A1 SUPPORT FOR THE SYNTHESIS OF MODULAR POLYMERS CHIRON MIMOTOPES PTY. LTD. (AU) 1995-09-20 EP disclosed
WO-1994028014-A2 PEPTIDE INHIBITORS OF UROKINASE RECEPTOR ACTIVITY CHIRON CORPORATION (US) 1994-12-08 WO disclosed
WO-1994011388-A1 SUPPORT FOR THE SYNTHESIS OF MODULAR POLYMERS CHIRON MIMOTOPES PTY. LTD. (AU) 1994-05-26 WO disclosed
WO-1994003483-A1 ENDOTHELIN RECEPTOR-BINDING COMPOUNDS CHIRON CORPORATION (US) 1994-02-17 WO disclosed